eSolutions, mHealth & HealthIT

Abstract

Funding will be used to accelerate the adoption of AI across European healthcare, expanding from an AI Medical Assistant to an AI-native Clinic Operating System and doubling down across European markets. The continent's health systems face a widening gap between demand and workforce and the WHO estimates a shortfall of 1.6 million health and social care workers in 2024, rising to 4 million by 2030². About the Scaleup Europe Fund The Scaleup Europe Fund, managed by EQT, is a commercially driven alternative investment fund backing ambitious European technology companies with the potential to become global leaders. https://eqtgroup.com/ Media contact Katya Escala | PR & Comms at Tandem Health katya.escala@tandemhealth.ai +44 07784097315 Sources [1] Tandem peer-reviewed research [2] Shortage of health and social care workers in Europe: need to bolster national health services and staff training [3] Population projections in the EU [4] Old-age dependency growing across EU regions

Abstract

Problemet: Trump lytter ikke. Alle bør i grunden sætte sig ned og læse det åbne brev, som stifteren af Anthropic, Dario Amodei, udsendte fredag, hvor han tager et opgør med sin teknologi. Lige så opsigtsvækkende, som det åbne brev er, lige så opsigtsvækkende er det, at rivalerne og nogle af de markante teknologibosser i USA slutter massivt op. Andre læser også

Abstract

Anthropic calls this the dual-use" problem, and it is the reason the company argues that filtering alone cannot keep an AI model safe in a field like biology, where the knowledge required to cure a disease and the knowledge required to engineer one are often the same knowledge, held by the same researcher, in the same paper. Geoffrey Hinton, the Nobel laureate, told the BBC that "a 10% chance seems not an unreasonable estimate to me," and Samuel Marks, who leads scalable oversight work at Anthropic, observed that "the more senior the employee, the more concerned they are." Three days later, Dario Amodei, Anthropic's chief executive, gave the argument its most formal statement yet, in an essay titled "We Must Pace the Frontier": "We must slow the pace at which we improve the capabilities of AI models." Sam Altman, OpenAI's chief executive, said his company would match Anthropic's commitment – going as far to delay their 2026 IPO – and Elon Musk posted simply that "Dario is right." Anthropic's public policy chief, Sarah Heck, took the argument to Washington, calling for federal legislation that would require frontier model testing and give regulators the power to block unsafe models. Speaking in Ireland on September 13, President Trump said he had no concerns about AI causing human extinction and dismissed the warnings as coming from "negative forces," adding: "We are leading China right now by a pretty good period, I would say a year." David Sacks, who now co-chairs the President's Council of Advisors on Science and Technology, told Altman and Amodei on X that he supported their right to slow down individually but made clear no federal mandate was coming: "I don't see what you see in the lab." House Speaker Mike Johnson opposed any moratorium on the grounds that "China will overtake" the United States. Insilico's founder, Alex Zhavoronkov, frames the competitive picture directly, saying his company now "competes with Chinese pharmaceutical companies on timelines." Geoffrey von Maltzahn, chief executive of Lila Sciences, put the stakes in national terms at Fortune's Brainstorm Tech conference: "Falling below the scientific intelligence of one's adversary at a corporate level, at a sovereign level, is almost like an unimaginable competitive disadvantage." Kimberly Powell, Nvidia's vice president of healthcare, made the same point from the funding side: "If we defund now, while the rest of the world leans in, we will be left behind." Five cases that turn the warning into something specific Anthropic's Threat Intelligence Report disclosed five documented attempts to use Claude models to support biological weapons development, a rare instance of an AI company publishing this kind of misuse data at all."

Abstract

Understanding compound selectivity is vital when designing novel pharmaceuticals. The extent of on- and off-target effects, or potential polypharmacology, informs modifications to develop safe and effective drugs. In this white paper we present a data-driven drug design method which visualizes binding site comparisons across a protein family, to deeply understand selectivity and pocket druggability. These Ensemble Hotspot Maps" are derived from peer-reviewed, experimentally-generated data in the Cambridge Structural Database, and automated to rapidly and visually guide target validation and drug design."

Abstract

With this new fund, Seed Capital is expanding its focus beyond Denmark to back 15–17 seed-stage companies across the Nordics in FinTech, Cybersecurity and Resilience, and AI-driven B2B solutions. The fund's investment thesis centers on three key verticals: Reinventing financial infrastructure (FinTech) Enhancing cybersecurity and resilience Transforming SMBs and enterprises (AI-driven B2B) Broadening into the Nordics is a natural move for us and it's been important for us to get the right team, with strong expertise and global mindset. This is also reflected in what we're looking for in the founders we back, founders building global winners" said Christian Broendum, Managing Partner at Seed Capital Strong LP Support and Early Investments Seed Capital's Fund V is backed by a diverse group of limited partners (LPs), including Realdania, EIFO, Dansk Vækst Kapital, Sampension, Lauritzen Fonden, Augustinus Fonden, family offices, and angel investors. With a new generation of partners, a proven platform, and fresh capital, Seed is well positioned to continue backing the most ambitious founders and strengthening the Danish and Nordic startup ecosystem," said Alexander Knudsen, investor at EIFO The fund has already made its first investments, including Norlix, Blackbird Coffee, Fortiv, Moxso, Pluto Markets, Repodo, and Oplane, with more to come."